WID-CLZ18

Whanin Pharmaceutical Company · Phase 1 active Small molecule

At a glance

Generic name	WID-CLZ18
Sponsor	Whanin Pharmaceutical Company
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Bioequivalence Study in Patients With Schizophrenia by Using Clozaril 100 mg Tablet (Clozapine) and WID-CLZ18 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

WID-CLZ18 CI brief — competitive landscape report
WID-CLZ18 updates RSS · CI watch RSS
Whanin Pharmaceutical Company portfolio CI